Your browser doesn't support javascript.
loading
Molecular testing of different cytologic preparations in patients with advanced lung adenocarcinoma: which yields the best results?
Vivero, Marina; Wang, Charlotte I; Jo, Vickie Y; Hollowell, Monica; Cibas, Edmund S; Lindeman, Neal I; Lowe, Alarice C.
Afiliação
  • Vivero M; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: mvivero@partners.org.
  • Wang CI; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
  • Jo VY; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Hollowell M; Department of Pathology, Boston Children's Hospital, Boston, Massachusetts.
  • Cibas ES; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Lindeman NI; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Lowe AC; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
J Am Soc Cytopathol ; 6(1): 16-23, 2017.
Article em En | MEDLINE | ID: mdl-31042629
ABSTRACT

INTRODUCTION:

This study constitutes the first systematic comparison of molecular results between different cytology preparations in patients with lung adenocarcinoma undergoing testing for EGFR, KRAS, and BRAF mutations. MATERIALS AND

METHODS:

115 archival cytology preparations (direct smears, ThinPrep preparations [TP], and cell blocks [CB]) from lung adenocarcinomas with known EGFR, KRAS, or BRAF mutations were tested and compared with clinical testing results. Results were compared between preparations and analyzed in relation to tumor purity and tumor cell content.

RESULTS:

82 (77%) of 106 informative cases were concordant with clinical testing results. There was no significant difference in the concordance rate between CB, TP, air-dried smears, or alcohol-fixed smears (P = 0.3803), nor between preparations with <25%, 25% to 50%, or >50% tumor purity (P = 0.1147). Concordance rates were lower in preparations with ≤100 tumor cells (P = 0.0002).

CONCLUSIONS:

Smears, TP, and CB are all valid substrates for molecular testing. Although tumor purity did not significantly affect results, low tumor content showed poorer performance. Recording tumor purity and content is recommended.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Am Soc Cytopathol Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Am Soc Cytopathol Ano de publicação: 2017 Tipo de documento: Article